Partial CXCR4 agonists can block the generation of immunosuppressive neutrophils

Sun, 2025/07/13

Partial CXCR4 agonists can block the generation of immunosuppressive neutrophils

The chemokine receptor CXCR4 partial agonist TFF2-MSA can reduce the generation of immunosuppressive neutrophils at the source, thereby synergizing with PD-1 inhibitors to suppress primary tumor growth and distant metastasis, and prolong the survival of gastric cancer mouse models. We witnessed the power of tumor's "long - arm jurisdiction" last month. Early last month, researchers from the Netherlands Cancer Institute found that breast cancer's remodeling of neutrophils starts with hematopoiesis in the bone marrow, leading to the generation of numerous immunosuppressive neutrophils, suppressi
Read More
New research reveals that the interaction between paxillin and FAK may influence cancer treatment resistance

Sun, 2025/07/13

New research reveals that the interaction between paxillin and FAK may influence cancer treatment resistance

This study adds important new details to a cell protein network that is difficult to characterize. Dr. Salgia and his team focused on paxillin, a protein that allows cells to adapt based on environmental changes. This helps cancer cells evolve and evade detection while triggering resistance to treatment. In a new study, an international research team led by scientists from City of Hope provided the most comprehensive elucidation to date of an elusive target in cancer treatment. They highlighted a complex signaling process involving paxillin that may be sensitive to treatment, even though the p
Read More
Advances in CAR-T Cell Therapy Research (I)

Sun, 2025/07/13

Advances in CAR-T Cell Therapy Research (I)

CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy) is a novel cell-based therapy that has been around for several years. It has only recently been refined and applied in clinical settings. This therapy has shown remarkable efficacy in treating acute leukemia and non-Hodgkin lymphoma and is considered one of the most promising cancer treatment approaches. Like all technologies, CAR-T has undergone a long evolutionary process, during which it has gradually matured. The crux of this new therapeutic strategy lies in an artificial receptor called the chimeric antigen receptor (CAR), which can i
Read More
Advances in CAR-T Cell Therapy Research (II)

Sun, 2025/07/13

Advances in CAR-T Cell Therapy Research (II)

Nature: HIV Viral Protein Nef Empowers Novel CAR-T Cells to Create Off-the-Shelf Donor Cells Ready for Immediate Use DOI: 10.1038/s41586-025-08657-0 CAR-T cell therapy is one of the most promising new cancer therapies to emerge in recent years. It involves extracting a patient's own T cells and genetically modifying them to recognize specific targets on the surface of cancer cells. A major limitation of this autologous CAR-T cell therapy, which uses the patient's own T cells, is that the cells must be customized for each treatment. This means patients must wait for their T cells to be modified
Read More
TOP30 Best-Selling Oncology Drugs Worldwide in 2024

Fri, 2025/06/06

TOP30 Best-Selling Oncology Drugs Worldwide in 2024

The current oncology drug market is at a critical period of product iteration and technological innovation. Traditional drugs, whose patents are expiring, are rapidly exiting the historical stage, while new therapeutic paradigms, fueled by emerging technologies like ADCs, are continuously reshaping the competitive landscape of the market. The oncology treatment sector has always been a focal market fiercely contested by major pharmaceutical giants. In 2024, its global market size has reached a new historical high, with the top 30 best-selling oncology drugs achieving a total sales of $147.4 bi
Read More
Scientists Uncover the Re-adenylation Role of Key Protein TENT5A in mRNA Vaccines

Fri, 2025/06/06

Scientists Uncover the Re-adenylation Role of Key Protein TENT5A in mRNA Vaccines

This research elucidates the molecular mechanisms behind the efficacy of mRNA vaccines, emphasizing the crucial role of TENT5A in enhancing mRNA stability and immune efficacy. Related Proteins In the global battle against the COVID-19 pandemic, mRNA vaccines have established a solid immune defense for humanity due to their efficient and rapid development and deployment. From Moderna to BioNTech-Pfizer, the successful application of these vaccines has not only transformed our understanding of vaccines but also inaugurated a new era for mRNA technology in the medical field. However, despite the
Read More
Analytical Methods for Human Insulin and Its Analogues(Part II)

Thu, 2025/06/05

Analytical Methods for Human Insulin and Its Analogues(Part II)

Biological Activity Analysis Methods Time-Resolved Fluorescence Immunoassay (TRFIA) Method Principle TRFIA is an immunoassay method based on time-resolved fluorescence technology. After insulin binds to cell receptors, it triggers tyrosine phosphorylation of the receptor's β subunit. The phosphorylated group forms a complex with anti-receptor α antibodies and europium-labeled antibodies in a double-antibody sandwich manner. By adding an acidic enhancement solution, the solid-phase antibody complex is dissociated and forms a chelate with diketone and octylphosphine molecules in the e
Read More
Analytical Methods for Human Insulin and Its Analogues

Thu, 2025/06/05

Analytical Methods for Human Insulin and Its Analogues

With the advancement of biotechnology, an increasing number of insulin analogues have been developed. To ensure the quality and safety of these drugs, comprehensive analyses are required. This article reviews various analytical methods for human insulin and its analogues, including structural analysis, impurity analysis, and biological activity analysis. Structure of Human Insulin and Its Analogues Structure of Human Insulin Human insulin consists of two chains, A and B, comprising a total of 51 amino acids: 21 in the A chain and 30 in the B chain. The two chains are connected by two disulfide
Read More